Acasti Pharma, Inc. (ACST) Upgraded by ValuEngine to Hold
ValuEngine upgraded shares of Acasti Pharma, Inc. (NASDAQ:ACST) from a sell rating to a hold rating in a report issued on Monday.
Shares of Acasti Pharma (NASDAQ:ACST) opened at $3.10 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.55 and a quick ratio of 4.55. Acasti Pharma has a 12-month low of $1.11 and a 12-month high of $3.36.
About Acasti Pharma
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).
Receive News & Stock Ratings for Acasti Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma Inc. and related stocks with our FREE daily email newsletter.